Archive for the ‘Our News’ Category



Welcoming Stephanie Kreml, M.D. as Newest Team Member

April 3rd, 2013
Posted by

I’m pleased to announce that Stephanie Kreml, M.D. has returned to Popper and Company, joining our core team of life science advisors as Principal.
 
Like all of our team members, Stephanie is committed to delivering perspective, value, and high-quality, hands-on service to clients across the life sciences spectrum.  As a practicing physician with an engineering background, Stephanie brings a unique multi-disciplinary perspective to helping life sciences companies address diverse healthcare issues.  She is an excellent addition to our existing team of experts whose operational backgrounds span clinical, technology, marketing and finance in a variety of capacities in the diagnostics, medical device, pharmaceuticals and digital health industries.
  Read the rest of this entry »

Tags: , , , , ,
Posted in Our News | Comments Off on Welcoming Stephanie Kreml, M.D. as Newest Team Member





Welcoming Head of Digital Health Strategy Paul Sonnier as Newest Team Member

March 13th, 2012
Posted by

I’m delighted to announce that Paul Sonnier, formerly a strategic advisor to Popper and Company, has joined our core team as Head of Digital Health Strategy.
 
Our core team provides diversity and expertise to resolve problems and create strategies in the health arena for our life science clients. Paul, who has recently been described as a catalyst in the wireless and mobile health field, brings his familiarity, insights and experience to our existing team of experts whose operational backgrounds span clinical, technology, marketing and finance in a variety of capacities in the diagnostics, medical device and pharmaceutical industries.
  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our News | 2 Comments »





Introducing Strategic Advisor Paul Sonnier: Digital Health Expert

January 11th, 2012
Posted by

Strategic advisors play an important role at Popper and Co. While our core team provides diversity and expertise to resolve problems and create strategies for companies in the life sciences arena, the unique advice and perspectives that come from our advisors is invaluable and often not available anywhere else.
 
Paul Sonnier, our third strategic advisor, already has given us—and you, our clients–invaluable advice on the brave new world of digital health. His perspective is vital to understanding the innovations that are opening doors to new paradigms in consumer health and influencing healthcare across the board.
 
Paul most recently served as vice president of partner development at the Wireless-Life Sciences Alliance (WLSA), a global trade organization that is dedicated to creating value and improving health globally, through the convergence of communications technologies, consumers, caregivers and all sectors of life sciences and technology.
  Read the rest of this entry »

Tags: , , , ,
Posted in Our News | Comments Off on Introducing Strategic Advisor Paul Sonnier: Digital Health Expert





State of Florida Providing Sunshine During #BIO2011

June 21st, 2011
Posted by

With news of life sciences research coming from around the world, it’s necessary to have our net spread far and wide to capture what’s most important and to convey these learnings. But we also know it’s important to stay on track of developments happening in our own waters whether they be near our offices in Maryland, Florida, New Mexico or Ontario.
 
Fortunately, we sometimes have opportunities to gather information about the life sciences industry both from afar and from our neighbors in one fell swoop. For example, from June 27 to 30, we’re attending the 2011 BIO International Conference in Washington, DC where thousands of life science leaders and professionals will gather from throughout the world.
 
While there, we’ll be networking with the global bioscience community, but we have a select eye on a panel on the 28th hosted by our Florida neighbors. We’re excited to note that this session—which is part of the personalized medicine and diagnostics track—includes colleagues of ours from M2Gen (represented with a key speaker) as well as Banyan Biomarkers, a company we helped to form. Both of these companies mark their successful rise in part to our shared belief in the importance of good clinical material for discovery and validation.
  Read the rest of this entry »

Posted in Our News | Comments Off on State of Florida Providing Sunshine During #BIO2011





Leveraging a Multi-Coastal Point of View of Life Sciences

May 17th, 2011
Posted by

Having a pulse on global trends in the biopharmaceutical industry requires a wide range of insights from experience in pharmacological research and technology development through to the core operations of large-scale and startup life science businesses. With this in mind, I’m pleased to welcome Dr. Andreas Muehler as our second strategic advisor. Dr. Muehler’s experience with preclinical and clinical development, major product launches, licensing, business development, and marketing provide him with a unique combination of technical and business perspectives.
 
In the United States, Dr. Muehler developed and managed multiple startup medical device and medical technology companies. Among them were 3TP LLC d/b/a CAD Sciences (White Plains, NY), a medical software company that was sold to iCAD Medical in 2008. Dr. Muehler was also President & CEO of MicroMRI Inc (Langhorne, PA), a medical device company that received FDA clearance for both hardware and software components during his tenure. Dr. Muehler has also been managing director of a German healthcare private equity fund, Palladius Healthcare GmbH in Munich, which acquired distressed medical device companies. Read the rest of Dr. Muehler’s impressive bio here.
  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our News | Comments Off on Leveraging a Multi-Coastal Point of View of Life Sciences





Introducing Our First Strategic Advisor: Dr. F. John Mills

May 4th, 2011
Posted by

Today’s post is an exciting one for me as I introduce our new strategic advisor, Dr. F. John Mills. With an extensive background that includes more than 25 years at the board and executive levels of major international corporations, Dr. Mills adds profound insights to our expanding operations and provides a new resource of vital information for our clients.
 
It’s difficult to encapsulate his entire career in a few short paragraphs and I encourage you to review his bio in the About section of our website. In brief, Dr. Mills served for three years as corporate senior vice president and president of clinical support services for Covance, Inc., where he was responsible for a $300 million per year clinical services division that employed more than 2,000 staff members globally. Prior to that, he was based in the United Kingdom as corporate vice president for Covance’s European clinical division. Earlier in his career, Dr. Mills held senior positions in Asia and Europe with Janssen Pharmaceutica, a division of Johnson & Johnson, Inc. His expertise includes extensive knowledge of clinical research outsourcing, pharmaceutical development, and global business management. Read the rest of this entry »

Tags: , , , , , ,
Posted in Our News | Comments Off on Introducing Our First Strategic Advisor: Dr. F. John Mills





After the Conference Ends: Thoughts Following Tri-Con 2011

March 3rd, 2011
Posted by

Now that the Molecular Med Tri-Con 2011 has ended and attendees are back at their offices, labs, practices, and/or hospitals – or perhaps have landed at their next business meeting or conference destination – it’s a good time to reflect on some of my general observations from the event.
 
The conference covered so much information that it would be impossible to review every topic. Following are a few areas that captured my attention and remain in my thoughts:

     

  • STEM CELLS – There was a lot of focus on induced pluripotent stem cells (iPSC), in particular how to better characterize and understand those cells. Pluripotent stem cells can differentiate, or change, to become any one of the many types of cells that make up an organism. These cells are already being used for applications such as drug testing and drug screening. Once they are induced to re-differentiate, iPSC can provide good models for disease: what some conference speakers referred to as a “disease in a dish.” Some discussion among presenters focused on the idea of isolating cells from patients, producing iPSC, and then reintroducing the produced cells into the patient to replace cells that have been damaged or lost as a result of disease – an elegant form of cell-based therapy. Although widespread use of this approach is likely a ways off, I’m both optimistic of the therapeutic potential and somewhat cautious because of regulatory hurdles and potential safety issues (including some data showing tumor production in animals). Read the rest of this entry »

Tags: , , , , , , , , , ,
Posted in Our News | Comments Off on After the Conference Ends: Thoughts Following Tri-Con 2011





TRI-CON – Diagnostics, Drug Discovery & Biologics: Oh My!

February 21st, 2011
Posted by

Sometimes, between the hotel room, the lectures, the networking, the power lunches and the data consumption at a conference, you’re on the plane home before you have time to reflect upon why you attended in the first place. I’m excited to be heading to the 18th International Molecular Medicine Tri-Conference in San Francisco this week—and I’m setting out my reasons for going this year beforehand.
 
I always look forward to this conference because of its balanced range of life science topics, including those with technical, scientific, business, strategy, regulatory and reimbursement slants. Within this balanced range of topics, the Tri-Con uses a channel structure to help attendees “tune in” where they can get the biggest bang for their buck. I’m excited to learn more about the following specifics within each channel: Read the rest of this entry »

Tags: , , , , , , , , , , ,
Posted in Our News | Comments Off on TRI-CON – Diagnostics, Drug Discovery & Biologics: Oh My!





Why Should the Life Science Industry Care About Davos?

January 27th, 2011
Posted by

CNN’s Dr. Sanjay Gupta went on air yesterday to explain why he, as a physician, is attending the World Economic Forum 2011 Annual Meeting taking place right now in Davos, Switzerland.
 
To paraphrase Dr. Gupta, health – and its impact on world economic development – is a big topic at the Davos meeting. He noted, “In terms of health care delivery, there is growing recognition by the forum that existing models simply aren’t sustainable in developed countries, and there simply isn’t enough access in the developing world. Some of that is old news, but the topics at Davos were chosen to address solutions in these areas. For example, I will be moderating panel discussions on topics ranging from personalized medicine to combating chronic disease.”
 
Because of the overarching health-related themes being discussed at Davos, the life science industry – particularly companies seeking to develop diagnostics and devices to address human illness – should focus on what’s taking place at Davos, as well. Following are a few of the critical themes being discussed that draw my attention:
  Read the rest of this entry »

Tags: , , , , , , , , ,
Posted in Our News | Comments Off on Why Should the Life Science Industry Care About Davos?





Channel surfing

December 2nd, 2010
Posted by

A year or so ago we at Popper and Company lumped Facebook and Twitter together when we thought about social media, just as many of you might have. What we knew is that these were two radically popular social media outlets. What we know now is that these are two very different types of social media channels.
 
As I see it, Facebook was and is an interesting way to reconnect with old friends and to stay in touch with family. I tend to have history or bloodlines in common with my Facebook friends. And, while I may indicate some of my interests by “liking” the Facebook page of a favorite sports team or musical artist, I prefer to tune in to Facebook to learn more about what the people I know are up to rather than to hear about broadsweeping policies, business interests, or global trends.
 
I see Twitter, on the other hand, as a way to connect not with people I know (necessarily), but with people whose interests I share. Facebook is like going to a family or class reunion; Twitter like attending an industry conference. I change the channel between these two social media tools depending on whether I’m in personal mode or in business mode. Read the rest of this entry »

Tags: , ,
Posted in Our News | Comments Off on Channel surfing





« Older Entries Newer Entries »